At ambient temperatures, neutral pH and ultralow concentrations (low nM), the bis(sulfonamido)bis(amido) oxidation catalyst [Fe{4-NOCH-1,2-(COCMeSO)CHMe}(OH)] () has been shown to catalyze the addition of an oxygen atom to microcystin-LR. This persistent bacterial toxin can contaminate surface waters and render drinking water sources unusable when nutrient concentrations favor cyanobacterial blooms. In mechanistic studies of this oxidation, while the pH was controlled with phosphate buffers, it became apparent that iron ejection from becomes increasingly problematic with increasing [phosphate] (0.3-1.0 M); is not noticeably impacted at low concentrations (0.01 M). At pH < 6.5 and [phosphate] ≥ 1.0 M, decays quickly, losing iron from the macrocycle. Iron ejection is surprisingly mechanistically complex; the pseudo-first-order rate constant has an unusual dependence on the total phosphate concentration ([P]), = [P] + [P], indicating two parallel pathways that are first and second order in [phosphate], respectively. The pH profiles in the 5.5-8.3 range for and are different: bell-shaped with a maximum of around pH 7 for and sigmoidal for with higher values at lower pH. Mechanistic proposals for the and pathways are detailed based on both the kinetic data and density functional theory analysis. The major difference between and is the involvement of different phosphate species, i.e., HPO () and HPO (); HPO is less acidic but more nucleophilic, which favors intramolecular rate-limiting Fe-N bond cleavage. Instead, HPO acts intermolecularly, where the kinetics suggest that [HPO] drives degradation.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.inorgchem.2c03854DOI Listing

Publication Analysis

Top Keywords

iron ejection
8
[p] [p]
8
hpo hpo
8
taml catalyst
4
catalyst resting
4
resting state
4
state lifetimes
4
lifetimes kinetic
4
kinetic mechanistic
4
mechanistic theoretical
4

Similar Publications

Background: Iron deficiency (ID) is currently defined as a serum ferritin level <100 or 100 to 299 ng/mL with transferrin saturation (TSAT) <20%. Serum ferritin and TSAT are currently used to define absolute and functional ID. However, individual markers of iron metabolism may be more informative than current arbitrary definitions of ID.

View Article and Find Full Text PDF

Aims: Hepcidin regulates plasma and tissue iron levels. We studied the association of hepcidin levels with the risk of incident heart failure (HF) and cardiac dysfunction in older adults.

Methods: We included adults from the ongoing, longitudinal Atherosclerosis Risk in Communities (ARIC) study who were free from prevalent anemia and HF at Visit 5 (2011-2013) and had available hepcidin and covariate data.

View Article and Find Full Text PDF

Background: Heart failure (HF) guidelines recommend routine testing for iron deficiency (ID) and, for those with ID, intravenous iron if the left ventricular ejection fraction is <50%. Guideline adherence to these recommendations by cardiologists in China is unknown.

Methods And Results: An independent academic web-based survey was designed and distributed via social networks to cardiologists across China.

View Article and Find Full Text PDF

Iron deficiency in acute coronary syndromes: prevalence and prognostic impact.

Porto Biomed J

January 2025

Rua Camilo Castelo Branco, Cardiology Department, São Bernardo Hospital, Setúbal Hospital Centre, Setúbal, Portugal.

Introduction And Objectives: Iron deficiency (ID) is a well-known prognostic marker in heart failure (HF), independent of anemia. However, its impact in acute coronary syndromes (ACSs) is not well established.

Methods: This is a retrospective analysis of patients admitted with ACS from January to December 2019.

View Article and Find Full Text PDF

Iron deficiency (ID) often coexists with heart failure (HF), and its prevalence increases with the severity of HF. Intravenous ferric carboxymaltose (FCM) has been associated with improvements in clinical outcomes, functional capacity, and quality of life (QoL) in patients with HF and ID. However, while earlier studies showed favorable results, more recent studies have failed to demonstrate significant improvements in outcomes for patients with heart failure with reduced ejection fraction (HFrEF) and ID.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!